A new research has demonstrated that drug bazedoxifene packs can cut the growth of breast cancer cells, even in resistant tumors. The findings show that medicines prescribed for osteoporosis cut growth both in estrogen-dependent breast cancer cells and in cells that had developed resistance to current targeted therapies, according to a Duke Cancer Institute study. “We found bazedoxifene binds...